Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by Professor Thomas Foltynie (UCL Queen Square ...